*Tozorakimab in patients with viral lung infection (TILIA)
Research type
Research Study
Full title
*A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).
IRAS ID
1006766
Contact name
Jay Vora
Contact email
Sponsor organisation
AstraZeneca AB
Eudract number
2022-003107-15
Clinicaltrials.gov Identifier
Research summary
This study is conducted to find out if the experimental drug called tozorakimab is safe and effective in treating severe viral lung infections that could potentially lead to Acute Respiratory Distress Syndrome (ARDS), and also to better understand the studied disease and associated health problems. ARDS is a life-threatening lung injury often treated with invasive mechanical ventilation (IMV, breathing support with a machine connected to a tube placed into the airway through the mouth or nose). Tozorakimab is a protein called an "antibody" designed to stick to interleukin-33 (IL-33), which is a protein made by the body known to play a role in inflammation in lungs caused by viral infection. It is hoped that stopping an excess of IL-33 from harming lungs will prevent progression of viral lung infection to severe lung injury and unfavourable outcomes. Approximately 2,352 people will take part. The study is funded by AstraZeneca AB.
REC name
London - Chelsea Research Ethics Committee
REC reference
22/LO/0795
Date of REC Opinion
19 Dec 2022
REC opinion
Further Information Favourable Opinion